Mansoor R. Mirza, MD, on Endometrial Cancer: New Findings on Dostarlimab-gxly Plus Chemotherapy
SGO 2023 Annual Meeting on Women’s Cancer
Mansoor R. Mirza, MD, of Copenhagen’s Rigshospitalet, discusses phase III data from the ENGOT-EN6-NSGO/GOG-3031/RUBY study, which showed that, compared with carboplatin and paclitaxel alone, dostarlimab-gxly plus carboplatin and paclitaxel increased progression-free survival in patients with primary advanced or recurrent endometrial cancer that is mismatch repair–deficient/microsatellite instability–high. An early trend toward improved overall survival was observed in all populations. This regimen may represent a new standard of care for patients, says Dr. Mirza.
The ASCO Post Staff
Ursula A. Matulonis, MD, of Dana-Farber Cancer Center discusses the ENGOT-OV16/NOVA study, which initially showed that niraparib maintenance therapy significantly prolonged progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of germline BRCA mutation or homologous recombination deficiency biomarker status. Here, Dr. Matulonis details the final phase III findings on overall survival and the long-term safety of niraparib in this population.
The ASCO Post Staff
Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses new findings on the combination of olaparib and selumetinib, which benefited patients with RAS-mutant ovarian and endometrial cancers. This combination will be explored further in these select cohorts in the upcoming ComboMATCH trial to clarify the relative contribution of each drug.
The ASCO Post Staff
Shannon N. Westin, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses results from the NOW study, which showed that neoadjuvant olaparib is feasible and has a good safety profile in patients with mutated, advanced-stage ovarian cancer. Even in patients with stage IV disease, surgical outcomes were favorable after two cycles of olaparib, justifying further study to determine whether PARP inhibitors can be given in lieu of chemotherapy in the neoadjuvant setting.
